10x Genomics, Inc.

Equities

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
27.59 ^USD	+2.57%		-1.25%	-50.70%

Apr. 18	Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating	MT
Mar. 26	10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay	CI

10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024

February 15, 2024 at 04:05 pm EST

10x Genomics, Inc. provided revenue guidance for the full year 2024. 10x Genomics expects full year 2024 revenue to be in the range of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.

Latest news about 10x Genomics, Inc.

Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating	Apr. 18	MT
10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay	Mar. 26	CI
10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel	Mar. 21	CI
10x Genomics Launches Two New Products With Single Cell Technology	Mar. 13	MT
10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products	Mar. 13	CI
Transcript : 10x Genomics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM	Mar. 05
UBS Adjusts 10x Genomics Price Target to $52 From $44, Maintains Neutral Rating	Feb. 21	MT
Stifel Cuts Price Target on 10x Genomics to $63 From $68, Maintains Buy Rating	Feb. 16	MT
10x Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
10x Genomics Q4 Net Loss Widens, Revenue Increases; Issues Outlook	Feb. 15	MT
Earnings Flash (TXG) 10X GENOMICS Reports Q4 Revenue $184M, vs. Street Est of $183.7M	Feb. 15	MT
Transcript : 10x Genomics, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
10x Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024	Feb. 15	CI
10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology	Feb. 07	CI
Transcript : 10x Genomics, Inc. Presents at 2024 AGBT General Meeting, Feb-07-2024 01:10 PM	Feb. 07
NanoString Starts Chapter 11 Bankruptcy; Exploring Strategic Options, Including Potential Sale	Feb. 05	MT
Barclays Adjusts Price Target on 10x Genomics to $55 From $45, Maintains Overweight Rating	Jan. 25	MT
James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024	Jan. 16	CI
Transcript : 10x Genomics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:00 AM	Jan. 08
10x Genomics Reports Preliminary Q4, Full Year 2023 Revenue	Jan. 08	MT
10x Genomics Launches Network to Accelerate Access to Xenium Proof-of-Concept Data	Dec. 21	MT
Wolfe Research Initiates 10x Genomics With Outperform Rating With $55 Price Target	Dec. 13	MT
North American Morning Briefing : Traders Await -2-	Dec. 13	DJ
BofA Securities Upgrades 10x Genomics to Neutral From Underperform, Adjusts Price Target to $54 From $36	Dec. 12	MT

Chart 10x Genomics, Inc.

Duration

Period

More charts

Company Profile

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-30 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for 10x Genomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.59 USD

Average target price

52.29 USD

Spread / Average Target

+89.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
10X GENOMICS, INC.	-50.70%	3.29B
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B
MYRIAD GENETICS, INC.	-5.02%	1.64B

Diagnostic & Testing Substances